Surgical outcomes of patients treated with ustekinumab vs. vedolizumab in inflammatory bowel disease: a matched case analysis
- 397 Downloads
The association between preoperative use of monoclonal antibodies in inflammatory bowel disease (IBD) patients and postoperative complications is controversial, especially for the latest approved biologics, ustekinumab and vedolizumab, where data is limited. We hypothesized that ustekinumab-treated patients would have a similar overall postoperative complication rate as vedolizumab-treated patients. The aim of this study was to compare postoperative complications in patients receiving preoperative ustekinumab vs. vedolizumab.
We queried our IRB-approved prospective database to identify Crohn’s patients who underwent colorectal surgery and pretreatment with ustekinumab or vedolizumab within 12 weeks of surgery. Ustekinumab-treated patients were matched to vedolizumab-treated patients based on sex, age ± 5 years, date of operation ± 3 years, and type of surgery. Paired univariate analysis and conditional logistic regression of the matched pairs were performed. Our primary outcome was the short-term postoperative complication rate. Secondary outcomes included infectious complications, readmission, reoperation, and length of stay.
A total of 103 patients with Crohn’s disease (CD) met the inclusion criteria (mean age 38.7 ± 13.4 years; male 51.2%). Overall, 30 patients received preoperative ustekinumab and 73 vedolizumab. In the univariate analysis, vedolizumab-treated patients had a higher postoperative complication rate (p = 0.009) and ileus rate (p = 0.015). After matching, 26 matched pairs were compared and logistic regression models demonstrated no significant difference in the primary outcome.
For our limited experience, the choice of preoperative biologic treatment between ustekinumab and vedolizumab should not be influenced by fear of surgical complications.
KeywordsUstekinumab Vedolizumab Biologics Colorectal surgery Outcomes Morbidity Mortality Comparison
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, et al. (2016) Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med [Internet]. [cited 2018 Jan 21];375(20):1946–60. Available from: https://doi.org/10.1056/NEJMoa1602773
- 2.Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel J-F, Sands BE, et al. (2013) Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med [Internet]. [cited 2018 Apr 5];369(8):711–21. Available from: https://doi.org/10.1056/NEJMoa1215739
- 3.Lightner AL, Raffals LE, Mathis KL, Cima RR, Tse CS, Pemberton JH, et al. (2016) Postoperative outcomes in vedolizumab-treated patients undergoing abdominal operations for inflammatory bowel disease. J Crohns Colitis [Internet]. [cited 2017 may 7];11(2):1–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27543504
- 4.Yamada A, Komaki Y, Patel N, Komaki F, Aelvoet AS, Tran AL, et al. (2017) Risk of postoperative complications among inflammatory bowel disease patients treated preoperatively with vedolizumab. Am J Gastroenterol [Internet]. [cited 2018 Jan 10];112(9):1423–9. Available from: https://doi.org/10.1038/ajg.2017.201
- 5.Lightner AL, McKenna NP, Tse CS, Hyman N, Smith R, Ovsepyan G, et al. (2017) Postoperative outcomes in ustekinumab-treated patients undergoing abdominal operations for Crohn’s disease. J Crohn’s Colitis [Internet]. Available from: https://doi.org/10.1093/ecco-jcc/jjx163/4694103
- 6.Centers for Disease Control and Prevention National Healthcare Safety Network. Surgical site infection (SSI) event. [Internet]. 2017 [cited 2017 Dec 27]. Available from: https://www.cdc.gov/nhsn/pdfs/pscmanual/9pscssicurrent.pdf
- 7.Gu J, Stocchi L, Remzi FH, Kiran RP. (2014) Total abdominal colectomy for severe ulcerative colitis: does the laparoscopic approach really have benefit? Surg Endosc [Internet]. [cited 2017 Dec 26];28(2):617–25. Available from: https://doi.org/10.1007/s00464-013-3218-7
- 8.Li W, Stocchi L, Cherla D, Liu G, Agostinelli A, Delaney CP, et al. (2017) Factors associated with hospital readmission following diverting ileostomy creation. Tech Coloproctol [Internet]. [cited 2017 Dec 28];21(8):641–8. Available from: https://doi.org/10.1007/s10151-017-1667-z
- 9.Food and Drug Administration. STELARA® (ustekinumab) injection, for subcutaneous or intravenous - FDA label [Internet]. 2016 [cited 2018 Apr 7]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761044lbl.pdf
- 10.Food and Drug Administration, Center for Drug Evaluation and Research. ENTYVIO (vedolizumab) for injection, for intravenous use - FDA label [Internet]. 2017 [cited 2018 Apr 7]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125476s000lbl.pdf
- 11.Li Y, Stocchi L, Cherla D, Liu X, Remzi FH (2016) Association of preoperative narcotic use with postoperative complications and prolonged length of hospital stay in patients with Crohn disease. JAMA Surg [Internet]. [cited 2018 Jan 21];151(8):726–34. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26913479
- 12.Golub R, Golub RW, Cantu RJ, Stein HD (1997) A multivariate analysis of factors contributing to leakage of intestinal anastomoses. J Am Coll Surg 184(4):364–372Google Scholar
- 15.Yamamoto T, Allan RN, Keighley MRB (2000) Risk factors for intra-abdominal sepsis after surgery in Crohn’s disease. Dis Colon Rectum [Internet] 43(8):1141–1145 Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00003453-200043080-00017 CrossRefGoogle Scholar
- 17.Varela JE, Wilson SE, Nguyen NT (2010) Laparoscopic surgery significantly reduces surgical-site infections compared with open surgery. Surg Endosc Other Interv Tech [Internet]. [cited 2016 Aug 7];24(2):270–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19533235
- 18.A study to evaluate the safety and efficacy of ustekinumab induction and maintenance therapy in participants with moderately to severely active ulcerative colitis (UNIFI) - ClinicalTrials.gov [Internet]. [cited 2018 Mar 11]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT02407236